A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis (IXORA-Q)

I1F-MC-RHBQ -

The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Genital Psoriasis, Psoriasis
What the trial is testing?
Ixekizumab
Could I receive a Placebo?
Yes
Enrollment Goal
149
Trial Dates
Apr 1, 2016 - Feb 21, 2018
How long will I be in the trial?
Your participation could last up to 16 months and include 15 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.